Cole Werble

Articles by Cole Werble

OPINION: Will Class-Wide REMS Programs Delay New Opioid Approvals?

ByCole Werble,Ramsey Baghdadi, Prevision Policy, LLC

March 3rd 2010

Class-wide opioid REMS will affect four million patients and require cooperation of more than 25 drug manufacturers

Latest Updated Articles

OPINION: Will Class-Wide REMS Programs Delay New Opioid Approvals?
March 3rd 2010

Trending on Pharmaceutical Commerce

Embedding Artificial Intelligence within Pharma Supply Chains

Pharma Pulse: PhRMA Sues to Block GLOBE Model and Bayer's $2.2B Ohio Site

Why PhRMA Sued to Block Medicare's GLOBE Pricing Model

LogiPharma USA 2026: Where Cold Chain Expertise Gaps Become Product Risk